Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCA-derived MSC therapy in renal transplant recipients with kidney transplant rejection
NL-OMON60503Phase 1Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, single-arm trial of MCA-derived mesenchymal stromal cells in kidney allograft rejection and Acute renal rejection (ARR), sponsored by Leiden University Medical Center. Started Oct 2024; status: recruiting.
02
Drugs
MCA-derived mesenchymal stromal cells
03
Conditions
kidney allograft rejectionAcute renal rejection (ARR)
Beyond the preview
Go deeper on NL-OMON60503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60503.